Publications by authors named "Mingen Liu"

Myeloid cells facilitate T cell immune evasion in cancer yet are pliable and have antitumor potential. Here, by cotargeting myeloid activation molecules, we leveraged the myeloid compartment as a therapeutic vulnerability in mouse models of pancreatic cancer. Myeloid cells in solid tumors expressed activation receptors including the pattern recognition receptor Dectin-1 and the TNF receptor superfamily member CD40.

View Article and Find Full Text PDF

Purpose: Determinants of treatment outcomes to chemotherapy-based regimens in metastatic pancreatic ductal adenocarcinoma (PDA) remain ill-defined. Our aim was to examine tissue-based correlates of treatment response and resistance using matched baseline and on-treatment biopsies collected from patients with PDA treated in the first-line metastatic setting.

Experimental Design: Patients with treatment-naïve metastatic PDA were enrolled in a Phase II trial (NCT02077881) investigating gemcitabine plus nab-paclitaxel in combination with indoximod, an orally administered small-molecule inhibitor of the IDO pathway.

View Article and Find Full Text PDF

The prevalence of heart failure is increasing, causing a tremendous burden on health care systems around the world. Although mortality rate of heart failure has been significantly reduced by several effective agents in the past 3 decades, yet it remains high in observational studies. More recently, several new classes of drugs emerged with significant efficacy in reducing mortality and hospitalization in chronic heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).

View Article and Find Full Text PDF
Article Synopsis
  • Type 2 diabetes is a growing global health issue, with projections suggesting over half a billion cases by 2030, increasing risks for heart-related complications.
  • Two new types of diabetes medications have shown promise in reducing cardiovascular issues through various clinical trials.
  • The Taiwan Society of Cardiology has created a consensus pathway to better integrate these therapies into patient care, supporting existing clinical guidelines.
View Article and Find Full Text PDF

Background: Patient satisfaction with oral anticoagulant (OAC) therapy is an important metric of care quality and has been associated with higher medication persistence. Among OACs, dabigatran has been shown to be non-inferior to vitamin K antagonists (VKAs) with increased ease of use for stroke prevention in patients with atrial fibrillation (AF). In this study, we sought to evaluate the expectations, convenience, and satisfaction of Taiwanese AF patients on dabigatran and VKA therapies as well as associated clinical outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • * Clinical trials initiated after a 2008 FDA mandate on cardiovascular safety for new diabetes medications have shown that some new agents can reduce cardiovascular (CV) risks and improve outcomes compared to older treatments.
  • * The Taiwan Society of Cardiology and the Diabetes Association of Republic of China have developed updated treatment guidelines aimed at managing type 2 diabetes in patients with various cardiovascular conditions and risk factors.
View Article and Find Full Text PDF

Background: An imbalanced fat or excess energy intake always results in obesity and increased serum/liver lipids, thus leading to metabolic syndromes. Given the bioactive components in black vinegar (BV), such as branched amino acids, phenolic profile, and mineral contents, we investigated the antiobesity effects of BV-based supplements in rats fed a high-fat diet (HFD).

Results: HFD (30% fat, w/w) feeding increased (P < 0.

View Article and Find Full Text PDF

What Is Known And Objective: Lorcaserin is a selective serotonin 2c receptor agonist approved as an anti-obesity agent. The additional cardiometabolic benefits associated with lorcaserin have not been conclusively established. The aim of the systematic review and meta-analysis is to examine the effects of lorcaserin on blood pressure, heart rate and other metabolic parameters in overweight and obese patients from randomized controlled clinical trials (RCTs).

View Article and Find Full Text PDF

Background: Alirocumab can provide significant reductions in low-density lipoprotein cholesterol (LDL-C). However, data regarding its efficacy and safety in Asians are limited.

Methods: A subgroup analysis of Taiwanese patients (n = 116) in a randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT, clinicaltrials.

View Article and Find Full Text PDF

Macrophages enforce antitumor immunity by engulfing and killing tumor cells. Although these functions are determined by a balance of stimulatory and inhibitory signals, the role of macrophage metabolism is unknown. Here, we study the capacity of macrophages to circumvent inhibitory activity mediated by CD47 on cancer cells.

View Article and Find Full Text PDF

Keratinocytes undergo significant structural remodeling during epidermal differentiation, including a broad transformation of the proteome coupled with a reduction in total cellular biomass. This suggests that intracellular digestion of proteins and organelles is necessary for keratinocyte differentiation. Here, we use both genetic and pharmacologic approaches to demonstrate that autophagy and lysosomal functions are required for keratinocyte differentiation in organotypic human skin.

View Article and Find Full Text PDF

Background: Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, has been shown to provide significant reductions in low-density lipoprotein cholesterol (LDL-C). Data about its efficacy and safety in patients from South Korea and Taiwan are limited.

Objective: ODYSSEY KT assessed the efficacy and safety of alirocumab in patients from South Korea and Taiwan.

View Article and Find Full Text PDF

Tumor, calor, rubor, and dolor describe four cardinal signs of inflammation. The fifth-functio laesa, or loss of function-was promulgated by Rudolf Virchow, who, in the 19th century, also noted an intricate link between inflammation and cancer. However, the role of cancer inflammation in driving loss of therapeutic efficacy has only recently been fully appreciated, as a result of molecular and immunohistochemical approaches applied in clinical medicine and the availability of novel agents for modulating inflammation.

View Article and Find Full Text PDF

Purpose: Local tumor growth is a major cause of morbidity and mortality in nearly 30% of patients with pancreatic ductal adenocarcinoma (PDAC). Radiotherapy is commonly used for local disease control in PDAC, but its efficacy is limited. We studied the impact of selectively intervening on radiotherapy-induced inflammation as an approach to overcome resistance to radiotherapy in PDAC.

View Article and Find Full Text PDF
Article Synopsis
  • Barrett's esophagus (BE) is a condition where the squamous cells in the esophagus change to a columnar type, which can lead to esophageal adenocarcinoma, but the specific origin of these cells is unclear.
  • The study investigated how Notch signaling impacts the initiation of BE and found that decreased levels of Notch receptors and ligands were present in BE samples, suggesting Notch inhibition may play a role in this transformation.
  • Experiments showed that inhibiting Notch signaling led to the transdifferentiation of esophageal cells into a BE-like state, driven in part by increased levels of KLF4, indicating a potential new mechanism for the development of BE.
View Article and Find Full Text PDF